Scinai Publishes Financial Results and Provides Business Update; Shareholders’ Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices unit, today announced that it will be showcasing its innovative I&I product pipeline in partnership meetings and exhibiting its CDMO services at the BIO-Europe 2024 conference, taking place November 4-6 in Stockholm, Sweden.

Scinai’s CEO, Mr. Amir Reichman, and CTO, Dr. Dalit Weinstein-Fischer will be holding meetings during the conference days with:

·         Prospective clients of the company’s end-to-end biologics CDMO services.

·         Potential pharma partners in the field of I&I interested in co-developing or in-licensing one of Scinai’s innovative NanoAbs.

·         Potential pharma partners in the field of dermatology interested in Scinai’s drug development program for local treatment of mild to moderate plaque psoriasis – “the Botox-like solution for psoriatic patients”

·         Institutional and private investors interested in SCNI’s value proposition.

Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies

Scinai Announces Signing of Loan Restructuring Agreement with the European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity

Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders’ Equity Requirement.